Healthy Volunteers
Conditions
Brief summary
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
Detailed description
This is a single center open label study to assess the effect of Dexpramipexole on the PK of Warfarin in Healthy Volunteers. The goals of this study are as follows: to assess the effect of dexpramipexole on the pharmacodynamics (PD) of warfarin, to assess the safety and tolerability of dexpramipexole when administered alone, and with warfarin, and to assess the PK of dexpramipexole when administered alone; to explore the influence of genetic variation on the PK and international normalized ratio (INR) of warfarin when administered alone, and with dexpramipexole; and to explore the influence of genetic variation on the PK of dexpramipexole when administered alone.
Interventions
DRUGWarfarin
single doses at specified time periods
DRUGDexpramipexole
multiple doses
Sponsors
Knopp Biosciences
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who, in the opinion of the investigator, are healthy as determined by medical history, physical examination, and 12 Lead ECG. * Adult males/females aged 18 to 55 years inclusive. * Male and female subjects of childbearing age must practice effective contraception during the study and up to 90 days after their last dose of study drug.
Exclusion criteria
* History of malignant disease, including solid tumors and hematologic malignancies. * Clinically significant current active infection or serious infection. * History of gastrointestinal bleeding, peptic ulcer disease, hemorrhoids or epistaxis. * Personal or family history of any bleeding disorder, and/or coagulation profile results outside of normal limits. * Known allergy or hypersensitivity to warfarin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of the effect of dexpramipexole on the pharmacokinetics (PK) parameters of the CYP2C9 probe substrate warfarin including: AUC: area under the plasma-concentration time curve over a specified time period and Cmax: Maximum observed plasma c | pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 144 hours after warfarin administration in each dosing period |
| PK parameters of dexpramipexole including but not limited to AUC: area under the plasma-concentration time curve over a specified time period and Cmax: Maximum observed plasma concentration | pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after administration of the morning dexpramipexole dose on Day 1 and Day 12 of Period 2 |
Countries
United States
Outcome results
None listed